Prelude Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-18,266
| Closed | -$613K | – | 1349 |
|
|
2025
Q1 | $613K | Hold |
18,266
| – | – | 0.05% | 382 |
|
|
2024
Q4 | $716K | Hold |
18,266
| – | – | 0.04% | 396 |
|
|
2024
Q3 | $719K | Sell |
18,266
-69
| -0.4% | -$2.72K | 0.04% | 427 |
|
|
2024
Q2 | $715K | Buy |
18,335
+24
| +0.1% | +$936 | 0.05% | 343 |
|
|
2024
Q1 | $788K | Sell |
18,311
-13,885
| -43% | -$598K | 0.04% | 409 |
|
|
2023
Q4 | $1.48M | Buy |
32,196
+16,438
| +104% | +$757K | 0.1% | 192 |
|
|
2023
Q3 | $538K | Buy |
15,758
+286
| +2% | +$9.77K | 0.04% | 366 |
|
|
2023
Q2 | $596K | Sell |
15,472
-6,540
| -30% | -$252K | 0.04% | 347 |
|
|
2023
Q1 | $788K | Buy |
22,012
+9,243
| +72% | +$331K | 0.05% | 318 |
|
|
2022
Q4 | $503K | Buy |
+12,769
| New | +$503K | 0.03% | 503 |
|
|
2017
Q3 | – | Sell |
-738
| Closed | -$2K | – | 1809 |
|
|
2017
Q2 | $2K | Buy |
+738
| New | +$2K | ﹤0.01% | 1409 |
|
|
2017
Q1 | – | Sell |
-34,928
| Closed | -$269K | – | 1759 |
|
|
2016
Q4 | $269K | Buy |
+34,928
| New | +$269K | 0.03% | 439 |
|
|
2015
Q3 | – | Sell |
-2,600
| Closed | -$30K | – | 1751 |
|
|
2015
Q2 | $30K | Buy |
2,600
+1,600
| +160% | +$18.5K | ﹤0.01% | 1191 |
|
|
2015
Q1 | $17K | Buy |
+1,000
| New | +$17K | ﹤0.01% | 1695 |
|